GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvation Bio Inc (NYSE:NUVB.WS) » Definitions » NonCurrent Deferred Liabilities

Nuvation Bio (Nuvation Bio) NonCurrent Deferred Liabilities : $0.18 Mil (As of Sep. 2021)


View and export this data going back to 2020. Start your Free Trial

What is Nuvation Bio NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Nuvation Bio's non-current deferred liabilities for the quarter that ended in Sep. 2021 was $0.18 Mil.

Nuvation Bio NonCurrent Deferred Liabilities Historical Data

The historical data trend for Nuvation Bio's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuvation Bio NonCurrent Deferred Liabilities Chart

Nuvation Bio Annual Data
Trend Dec20 Dec21
NonCurrent Deferred Liabilities
- -

Nuvation Bio Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
NonCurrent Deferred Liabilities Get a 7-Day Free Trial - 0.17 0.18 0.18 -

Nuvation Bio NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of Nuvation Bio's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Nuvation Bio (Nuvation Bio) Business Description

Industry
Comparable Companies
Traded in Other Exchanges
N/A
Address
1500 Broadway, Suite 1401, New York, NY, USA, 10036
Nuvation Bio Inc is a biopharmaceutical company. The company is engaged in developing therapeutic candidates for the unmet needs in oncology. The firm operates in pharmaceutical, biotechnology and other related markets that develop small molecules and drug conjugates as treatments for cancer patients.